{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+System&page=43", "query": { "condition": "Digestive System", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 14965, "total_pages": 1497, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+System&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Digestive+System&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T20:45:33.446Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05685602", "title": "CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2023-06-12", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 26, "location_summary": "Duarte, California • Irvine, California • Orange, California + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05685602" }, { "nct_id": "NCT03479645", "title": "Serial SMS Reminders and an Opt-out Mailed FIT Kits to Improve Colorectal Screening Participation: A Single Center RCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bowel Cancer", "Colon Cancer" ], "interventions": [ { "name": "Serial text messages and mailed FIT kit", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "50 Years to 74 Years" }, "enrollment_count": 440, "start_date": "2018-03-23", "completion_date": "2018-06-16", "has_results": false, "last_update_posted_date": "2019-07-22", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03479645" }, { "nct_id": "NCT02396745", "title": "TECR & ECM Placement for Esophageal High Grade Dysplasia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Barrett Esophagus", "Esophagus", "High Grade Dysplasia" ], "interventions": [ { "name": "Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1, "start_date": "2016-01-25", "completion_date": "2018-03-22", "has_results": true, "last_update_posted_date": "2019-03-19", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02396745" }, { "nct_id": "NCT02442687", "title": "JKB-121 for the Treatment of Nonalcoholic Steatohepatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "JKB-121: 5 mg twice daily", "type": "DRUG" }, { "name": "JKB-121: 10 mg twice daily", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Manal Abdelmalek", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-08-01", "completion_date": "2017-09-24", "has_results": true, "last_update_posted_date": "2019-01-07", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 8, "location_summary": "Dothan, Alabama • Chicago, Illinois • Las Vegas, Nevada + 5 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02442687" }, { "nct_id": "NCT00005906", "title": "Treatment With Octreotide in Patients With Lymphangioleiomyomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphangioleiomyomatosis", "Lymphangiomyomas", "Pleural Effusions", "Ascites" ], "interventions": [ { "name": "Octreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 4, "start_date": "2000-06", "completion_date": null, "has_results": true, "last_update_posted_date": "2010-04-30", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005906" }, { "nct_id": "NCT07259304", "title": "Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Central Nervous System Neoplasm", "Clinical Stage I Cutaneous Melanoma AJCC v8", "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8", "Clinical Stage II Cutaneous Melanoma AJCC v8", "Clinical Stage IIA Cutaneous Melanoma AJCC v8", "Clinical Stage IIB Cutaneous Melanoma AJCC v8", "Clinical Stage IIC Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Hodgkin Lymphoma", "Malignant Bone Neoplasm", "Malignant Brain Neoplasm", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Non-Hodgkin Lymphoma", "Pathologic Stage I Cutaneous Melanoma AJCC v8", "Pathologic Stage IA Cutaneous Melanoma AJCC v8", "Pathologic Stage IB Cutaneous Melanoma AJCC v8", "Pathologic Stage II Cutaneous Melanoma AJCC v8", "Pathologic Stage IIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIC Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Stage I Cervical Cancer AJCC v8", "Stage I Colorectal Cancer AJCC v8", "Stage I Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage I Ovarian Cancer AJCC v8", "Stage I Thyroid Gland Medullary Carcinoma AJCC v8", "Stage I Uterine Corpus Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Ovarian Cancer AJCC v8", "Stage IA Uterine Corpus Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB Cervical Cancer AJCC v8", "Stage IB Ovarian Cancer AJCC v8", "Stage IB Uterine Corpus Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IB2 Cervical Cancer AJCC v8", "Stage IC Ovarian Cancer AJCC v8", "Stage II Cervical Cancer AJCC v8", "Stage II Colorectal Cancer AJCC v8", "Stage II Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage II Ovarian Cancer AJCC v8", "Stage II Thyroid Gland Medullary Carcinoma AJCC v8", "Stage II Uterine Corpus Cancer AJCC v8", "Stage IIA Cervical Cancer AJCC v8", "Stage IIA Colorectal Cancer AJCC v8", "Stage IIA Ovarian Cancer AJCC v8", "Stage IIA1 Cervical Cancer AJCC v8", "Stage IIA2 Cervical Cancer AJCC v8", "Stage IIB Cervical Cancer AJCC v8", "Stage IIB Colorectal Cancer AJCC v8", "Stage IIB Ovarian Cancer AJCC v8", "Stage IIC Colorectal Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Thyroid Gland Medullary Carcinoma AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 173, "start_date": "2021-11-24", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 3, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07259304" }, { "nct_id": "NCT01735552", "title": "Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anemia of Prematurity", "Necrotizing Enterocolitis" ], "interventions": [], "intervention_types": [], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "12 Weeks", "sex": "ALL", "summary": "Up to 12 Weeks" }, "enrollment_count": 12, "start_date": "2012-06", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2015-05-05", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 3, "location_summary": "Murray, Utah • Salt Lake City, Utah", "locations": [ { "city": "Murray", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01735552" }, { "nct_id": "NCT00015652", "title": "Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Peginterferon alfa-2b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": null, "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00015652" }, { "nct_id": "NCT02869152", "title": "Sentinel Lymph Node Mapping in Rectal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rectal Neoplasms" ], "interventions": [ { "name": "Endoscopic injection of 99mTc-sulfur colloid", "type": "OTHER" }, { "name": "Endoscopic injection of ICG", "type": "OTHER" }, { "name": "Endoscopic injection of Spot", "type": "OTHER" }, { "name": "Flexible sigmoidoscopy", "type": "PROCEDURE" }, { "name": "Endoscopic NIR imaging and gamma probe", "type": "PROCEDURE" }, { "name": "Dissection of sentinel lymph node(s)", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2016-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02869152" }, { "nct_id": "NCT01508130", "title": "An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [], "intervention_types": [], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 672, "start_date": "2012-01-31", "completion_date": "2014-03-31", "has_results": true, "last_update_posted_date": "2017-04-10", "last_synced_at": "2026-10-30T20:45:33.446Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01508130" } ] }